- Open
- 421.50
- High
- 424.80
- Low
- 422.50
- Close
- 421.05
- Change
- +10.00 (2.44%)
- Volume
- 29,970
| 11 Aug 2026 | 14:55:42 | Exercise of Share Options and Total Voting Rights |
| 31 Jul 2026 | 10:05:21 | Exercise of Share Options and Total Voting Rights |
| 27 Jul 2026 | 07:00:09 | 3T Pro commercial launch |
| 22 Jul 2026 | 07:00:01 | Positive Trading Update |
| 7 Jul 2026 | 15:04:32 | Holding(s) in Company |
| 30 Oct 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 16 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 22 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
| 2 Mar 2026 | Find out how Tristel could ‘clean up’ in the US | |
| 22 Jan 2026 | Tristel confirms FY outlook | |
| 22 Jan 2026 | Tristel reveals strong start to year |
Tristel plc develops and manufactures infection control products, primarily focusing on the healthcare sector. The company offers a range of disinfectants and sterilants that are used in hospitals and other medical facilities to maintain hygiene and prevent contamination. Tristel operates mainly in the United Kingdom and has a growing international presence, with significant sales in Europe and the Asia-Pacific region. Its business model relies on direct sales and a network of distributors to reach various healthcare customers globally.
| 11 Aug 2026 | 14:55:42 | Exercise of Share Options and Total Voting Rights |
| 31 Jul 2026 | 10:05:21 | Exercise of Share Options and Total Voting Rights |
| 27 Jul 2026 | 07:00:09 | 3T Pro commercial launch |
| 22 Jul 2026 | 07:00:01 | Positive Trading Update |
| 7 Jul 2026 | 15:04:32 | Holding(s) in Company |
| 30 Oct 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 16 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 22 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
| 2 Mar 2026 | Find out how Tristel could ‘clean up’ in the US | |
| 22 Jan 2026 | Tristel confirms FY outlook | |
| 22 Jan 2026 | Tristel reveals strong start to year |
Tristel plc develops and manufactures infection control products, primarily focusing on the healthcare sector. The company offers a range of disinfectants and sterilants that are used in hospitals and other medical facilities to maintain hygiene and prevent contamination. Tristel operates mainly in the United Kingdom and has a growing international presence, with significant sales in Europe and the Asia-Pacific region. Its business model relies on direct sales and a network of distributors to reach various healthcare customers globally.
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £616m | +0.4% | |
| £304m | -0.1% | |
| £282m | -0.1% | |
TSTLTristel PLC | £202m | +0.1% |
| £105m | +0.3% | |
| £87m | +0.1% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £616m | +0.4% | |
| £304m | -0.1% | |
| £282m | -0.1% | |
TSTLTristel PLC | £202m | +0.1% |
| £105m | +0.3% | |
| £87m | +0.1% |